Arbutus Biopharma Corp. reported its financial results for the quarter ended March 31, 2025. The company posted a total revenue of $1.8 million, marking an increase from $1.5 million in the same period of 2024. This growth of $0.3 million was primarily driven by an increase in revenue recognition of the upfront license fee received in 2022 from Qilu, the Company's collaboration partner in China, Hong Kong, Macau, and Taiwan. However, this was partially offset by a decrease in license royalty revenues due to a decline in Alnylam's sales of ONPATTRO. The company's net loss for the quarter was $24.5 million, compared to a net loss of $17.9 million for the same quarter in 2024. Operating expenses increased significantly to $27.5 million from $20.9 million in the previous year, influenced by restructuring costs amounting to $12.4 million. The increase in net loss is also reflected in the loss from operations, which was $25.7 million, up from $19.4 million in the previous year. As of March 31, 2025, Arbutus Biopharma Corp. had cash, cash equivalents, and investments in marketable securities totaling $112.7 million, a decrease from $122.6 million as of December 31, 2024. This decline was primarily due to $13.4 million used in operating activities, offset by $2.7 million from the exercise of employee stock options. Additionally, the company reported 191.5 million common shares issued and outstanding as of March 31, 2025, with Roivant Sciences Ltd. holding approximately 20% of these shares.